Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits-Reference-Cited by-同舟云学术

Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Egbelowo Oluwaseun¹,Sarathy Jansy P.²,Gausi Kamunkhwala¹,Zimmerman Matthew D.²,Wang Han²,Wijnant Gert-Jan²,Kaya Firat²,Gengenbacher Martin²^ORCID,Van Nhi³,Degefu Yonatan³,Nacy Carol⁴,Aldridge Bree B.³,Carter Claire L.²,Denti Paolo¹^ORCID,Dartois Véronique²⁵^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

3. Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA

4. Sequella, Inc., Rockville, Maryland, USA

5. Hackensack School of Medicine, Hackensack Meridian Health, Nutley, New Jersey, USA

Abstract

Drug-resistant tuberculosis (TB) accounts for over 20% of all fatalities due to drug-resistant pathogens. With recently approved drugs and a promising drug candidate pipeline, the challenge faced by clinical developers is prioritization of drug combinations with the best potential to improve cure rates and shorten treatment duration.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00024-21

Reference75 articles.

1. World Health Organization. 2020. Global tuberculosis report 2020. WHO, Geneva, Switzerland.

2. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020

3. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

4. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

5. TB Alliance regimen development for multidrug-resistant tuberculosis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen;Nature Communications;2024-08-25

2. Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25

3. Modeling visceral leishmaniasis and tuberculosis co-infection dynamics;Frontiers in Applied Mathematics and Statistics;2023-05-15

4. Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of Mycobacterium tuberculosis;Tuberculosis;2023-03

5. The clinical-stage drug BTZ-043 accumulates in tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis;2023-02-28